Undisclosed NK+T / Nkarta Therap, CRISPR Therap - LARVOL DELTA

Large-scale expansion and engineering of human NK cells sourced from peripheral blood versus umbilical cord blood (SITC 2022) - "Methods PBNK and CBNK cells were expanded using either a 14-day protocol and a single stimulation with Nkarta’s NKSTIM cell line plus IL-2, or with 5 stimulations over 70 days...Conclusions We demonstrate healthy donor-derived PBNK cells can expand over 250 billion-fold while maintaining potency. These results show robust expansion capability of educated, potent NK cells and provide a rationale for the development of off-the-shelf CAR NK cell therapies using NK cells from donors selected to provide optimal product characteristics."

Oncology • B3GAT1 • CD19 • IL12A • IL15 • IL18 • IL2 • KLRC1